Makateb Ali, Soleymanzadeh Mahdi, Soleiman-Meigooni Saeed, Asgari Ali, Etemadi Mohammad Reza, Mafi Amir Reza, Mohammadi Nader
Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran.
Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
J Curr Ophthalmol. 2024 Aug 10;35(4):337-344. doi: 10.4103/joco.joco_251_23. eCollection 2023 Oct-Dec.
To investigate the effect of topical Polyvinylpyrrolidone-iodine (PVP-I) 0.6% on the clinical course of adenoviral keratoconjunctivitis compared with PVP-I 1% and artificial tears.
We prospectively enrolled all patients over 18 years of age with a polymerase chain reaction (PCR)-confirmed diagnosis of adenoviral keratoconjunctivitis who presented to the hospital between November 2022 and June 2023. Patients were randomized into 3 groups: artificial tears (control), PVP-I 1%, and PVP-I 0.6% eye drops, 4 times daily for 5 days. Clinical signs at presentation and at 6 follow-up visits during the 1 3 weeks of the acute phase were recorded. Patients were also followed up at 1 and 3 months.
Ninety-four patients completed the study, of which 30, 31, and 33 were in the control, PVP-I 1%, and PVP-I 0.6% groups, respectively. The mean age of the patients was 37.2 years (interquartile range: 25-46). The PCR result was positive in 75.6% of patients with the clinical suspicion. PVP-I, regardless of the concentration, was superior to the artificial tears in terms of time to resolution of lid swelling, discharge, and incidence of subsequent subepithelial infiltrates ( < 0.05). However, a concentration of 0.6% was equivalent to 1%. No significant adverse events were reported in any group.
The PVP-I 0.6% topical drops are safe and well tolerated in patients with acute adenoviral keratoconjunctivitis. It can be substituted for the 1% solution as it has comparable effects in improving the clinical course and reducing subsequent complications.
研究0.6%聚维酮碘（PVP-I）局部用药与1% PVP-I及人工泪液相比，对腺病毒性角结膜炎临床病程的影响。
我们前瞻性纳入了2022年11月至2023年6月期间到医院就诊、经聚合酶链反应（PCR）确诊为腺病毒性角结膜炎的所有18岁以上患者。患者被随机分为3组：人工泪液（对照组）、1% PVP-I和0.6% PVP-I滴眼液，每天滴眼4次，持续5天。记录急性期13周内就诊时及6次随访时的临床体征。患者还在1个月和3个月时进行随访。
94例患者完成了研究，其中对照组30例、1% PVP-I组31例、0.6% PVP-I组33例。患者的平均年龄为37.2岁（四分位间距：25 - 46岁）。临床疑似患者中75.6%的PCR结果呈阳性。无论浓度如何，PVP-I在睑肿胀消退时间、分泌物以及后续上皮下浸润发生率方面均优于人工泪液（P<0.05）。然而，0.6%的浓度与1%的浓度效果相当。任何组均未报告显著不良事件。
0.6% PVP-I局部滴眼液在急性腺病毒性角结膜炎患者中安全且耐受性良好。由于其在改善临床病程和减少后续并发症方面具有相当的效果，故可替代1%溶液。
